BioSpace News Archive

Adagene, Inc. has received notification from the FDA to proceed on its Investigational New Drug (IND) application to study its lead product (ADG-106) in patients with advanced solid tumors and non-Hodgkin lymphoma.

The U.S. House of Representatives’ Energy & Commerce Subcommittee on Health will hold a hearing on the 340B drug pricing program Wednesday, July 11th. PhRMA, the drug industry trade group, ran online ads in Politico today, falsely claiming, ‘... every stakeholder has raised concerns with the 340B program.’